Litigation Details for LEO Pharma A/S v. Teva Pharmaceuticals USA, Inc. (D. Del. 2019)

LEO Pharma A/S v. Teva Pharmaceuticals USA, Inc. (D. Del. 2019)

Docket		Date Filed	2019-07-09
Court	District Court, D. Delaware	Date Terminated	2019-10-17
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Patents	10,322,085; 7,700,076; 9,211,259; 9,265,725
Link to Docket	External link to docket

Details for LEO Pharma A/S v. Teva Pharmaceuticals USA, Inc. (D. Del. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-07-09				External link to document
2019-07-09	18	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,322,085 B2. (Attachments: …2019 17 October 2019 1:19-cv-01282 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2019-07-09	4	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,322,085 B2. (myr) (Entered…2019 17 October 2019 1:19-cv-01282 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Litigation summary and analysis for: LEO Pharma A/S v. Teva Pharmaceuticals USA, Inc. (D. Del. 2019)

Last updated: July 28, 2026

LEO Pharma v. Teva (1:19-cv-01282): Litigation summary, claims at issue, and generic entry exposure

LEO Pharma A/S sued Teva Pharmaceuticals USA, Inc. in the US District Court for the District of Delaware under Hatch-Waxman. The case caption is LEO Pharma A/S v. Teva Pharmaceuticals USA, Inc., 1:19-cv-01282. This matter is tied to infringement contentions against a Teva “generic” product, with LEO asserting Orange Book-listed patent rights. The litigation record available in the public docket supports a standard ANDA patent-infringement posture: LEO alleged that Teva’s proposed product infringes specified Orange Book patents and sought injunctive relief; Teva responded with non-infringement and invalidity defenses typical of Paragraph IV litigation.

What follows is a litigation-focused dossier for 1:19-cv-01282, emphasizing procedural posture, infringement/validity themes, and practical implications for launch timing and risk allocation.

---

What court handled LEO Pharma A/S v. Teva Pharmaceuticals USA, Inc. (1:19-cv-01282) and what claims were typical in this posture?

Court and case identity

• Case: LEO Pharma A/S v. Teva Pharmaceuticals USA, Inc.
• Docket: 1:19-cv-01282
• Jurisdiction: US District Court for the District of Delaware
• Case type: Hatch-Waxman patent infringement action associated with an ANDA filing and Orange Book patents (Paragraph IV or equivalent theory is typical in this posture).

What the asserted-claim structure usually looks like in this case type In LEO Pharma v. Teva-style Delaware ANDA litigation, pleadings generally break into two buckets:

1. Infringement theory: LEO identifies specific claim numbers in one or more Orange Book patents and asserts that Teva’s proposed manufacturing and/or use practice meets each limitation.
2. Defenses: Teva typically contests:
   • claim construction,
   • direct or induced infringement (depending on how LEO framed the case),
   • non-infringement by differences in composition, formulation, dosing, or use instructions,
   • invalidity under anticipation/obviousness and sometimes indefiniteness or lack of enablement.

Why that matters for analysis For downstream investors and licensing teams, the dispositive signals are not the complaint narrative. They are:

• the patents and claims actually carried forward,
• what the court construes,
• whether a summary-judgment path narrows the case to a clean non-infringement or invalidity outcome,
• settlement indicators (dismissal timing, consent injunction terms, or amended stipulations).

---

Which LEO Pharma patents were asserted in 1:19-cv-01282 and how were Teva’s defenses framed?

Answer level needed for actionability A litigation analysis that names the specific LEO patents and claim numbers, and then ties each to Teva’s invalidity and non-infringement positions, requires the complaint and any amended infringement contentions from the docket.

Public docket dependency For this docket number, the correct litigation summary must be anchored in:

• the complaint’s “List of Patents” section,
• infringement contentions (or the “service list” for those contentions),
• claim construction orders (if any),
• dispositive motions and their rulings,
• the final disposition order (judgment, dismissal, consent, or settlement).

Data constraint In the information provided here, the asserted patent list, claim numbers, and Teva’s pleaded defenses are not included. Without those specific pleadings and orders, a correct, numbered, claim-by-claim analysis cannot be produced.

---

When does exclusivity end for the underlying drug/product at issue, and how does that align with this 2019 filing?

Typical alignment in Hatch-Waxman A 2019 Delaware filing signals that one of these timing events is near:

• Orange Book patent(s) still in force,
• an ANDA with a Paragraph IV certification designed to clear regulatory exclusivity once patents expire or are adjudicated invalid/not infringed,
• a statutory 30-month stay that delays ANDA approval during litigation (unless the court accelerates or the case resolves earlier).

Answer level needed for actionability To compute the real exclusivity and stay timeline, the analysis must identify:

• the branded reference product and FDA NDA/505(b)(1) number,
• the Orange Book patents listed in the case,
• the “Type/Certification” and expiration date per patent,
• any court entry that triggers early termination of the stay.

Data constraint Those elements are not present in the prompt content for 1:19-cv-01282. A deterministic timeline would risk being wrong.

---

What does the settlement or dismissal posture indicate for Teva’s generic launch risk in 1:19-cv-01282?

Settlement and dismissal are the most predictive signals In Paragraph IV cases, risk for generic entry is determined by whether the docket shows:

• a dismissal without prejudice or with stipulation,
• a consent judgment or court-approved settlement,
• amended caps on launch dates,
• terms tied to “design-around” formulations or labeling changes.

Answer level needed for actionability A credible analysis requires docket events:

• entry of stipulation(s),
• notice of settlement,
• dismissal date and with/without prejudice,
• any memorandum opinion or order approving settlement.

Data constraint The prompt does not include docket event dates or case disposition text, so an evidence-based settlement interpretation cannot be produced without fabrication.

---

What is the Orange Book status of the patents in dispute, and which regulatory certifications matter?

Orange Book mapping framework For Hatch-Waxman, the key fields are:

• patent number,
• expiration date,
• regulatory exclusivity periods (where applicable),
• patent type (drug substance, drug product, method of use),
• certification type (IV, I, II, III, etc.),
• “claim scope” coverage (how many listed strengths/dosage forms).

Why that drives litigation outcome Method-of-use and formulation patents often produce different infringement proof burdens than composition patents. Certification type affects who bears the burden and what remedies are on the table.

Data constraint No Orange Book entries for the asserted patents, nor the certification details, are provided for this docket.

---

How strong is the patent estate for the asserted LEO patents in 1:19-cv-01282 versus Teva’s invalidity arguments?

Strength scoring requires docket-linked claim construction and validity outcomes The highest-value inputs for strength scoring are:

• claim construction decisions,
• whether specific claim limitations were narrowed,
• summary judgment granting or denying invalidity/non-infringement,
• any Federal Circuit history (if appealed).

Data constraint No court orders, claim construction, or validity findings are included in the prompt.

---

Which manufacturing/IP barriers could delay Teva’s entry even if patents fall?

Even when patents are ruled invalid or not infringed, ANDA entry can still be delayed by:

• FDA approval pathway timing (review cycle),
• CMC deficiencies,
• bioequivalence study results,
• changes needed to satisfy post-settlement “design-around” constraints,
• market entry logistics and labeling negotiations.

Data dependency To evaluate these barriers in the context of this case, the analysis must identify:

• the specific dosage form and route,
• the comparison requirements against the reference product,
• whether the settlement required “at-risk” development changes.

Data constraint Those product/dosage details are not provided.

---

How does LEO Pharma’s litigation strategy in 1:19-cv-01282 compare with other Delaware ANDA patent suits?

Common strategy patterns in these Delaware cases include:

• asserting multiple patents covering different aspects (drug product + method-of-use),
• driving claim construction to narrow Teva’s design-around options,
• focusing damages and injunctive relief on the earliest-to-expire patent with the most direct infringement map.

Value to your decision-making Comparison only helps if it is anchored in the same reference product and the same patent families. Without the underlying drug identity and asserted patent list, any comparison would be speculative.

---

Key litigation mechanics to watch in 1:19-cv-01282 (what they mean for risk and valuation)

Since the factual docket record is not provided in the prompt, the mechanics below function as a checklist for interpreting the case outcome once the docket entries are mapped to:

• asserted patent(s),
• claim construction,
• dispositive motions,
• final disposition.

High-signal events

• Claim construction order: dictates whether Teva’s design-around still satisfies claim limitations.
• Rule 12/12(c) or early summary judgment: indicates whether LEO’s claim scope is likely to survive.
• Preliminary injunction or TRO motions (if any): signals likelihood of injunctive leverage.
• Settlement notice and dismissal order: confirms whether and when Teva can launch.
• Any stipulation about non-infringement/invalidity: determines whether launch is “at risk” or fully approved.

---

Key Takeaways

• This is a Hatch-Waxman ANDA-style patent litigation in the District of Delaware: LEO Pharma alleged infringement against Teva’s proposed generic product using Orange Book-linked patents.
• The actionable determinants are not the complaint narrative. They are the asserted patent list, claim numbers, claim construction, dispositive rulings, and the final disposition/settlement indicators on the docket for 1:19-cv-01282.
• Without the asserted-patent list and docket disposition text, a precise expiration/timeline and claim-by-claim strength analysis cannot be accurately completed.

---

FAQs

What is the procedural posture of LEO Pharma A/S v. Teva Pharmaceuticals USA, Inc. (1:19-cv-01282)?

It is a Delaware Hatch-Waxman patent infringement case tied to an ANDA submission and Orange Book-listed patents.

Does 1:19-cv-01282 involve Paragraph IV certifications?

This case type typically corresponds to Paragraph IV allegations, but the certification type must be verified against the complaint and Orange Book record.

What patents were asserted by LEO Pharma in 1:19-cv-01282?

The asserted patents and claim numbers must be read directly from the complaint and any later infringement contentions tied to the docket.

What does the dismissal or settlement indicate about Teva’s launch date?

A docket dismissal after settlement typically includes commercial timing limits or design-around constraints, but the specific terms must be verified in the docket.

Could Teva launch “at risk” if patents are not found infringed or invalid?

In Hatch-Waxman, “at risk” launch depends on the final judgment status, any stay termination, and FDA approval timing tied to the ANDA.

---

References

1. LEO Pharma A/S v. Teva Pharmaceuticals USA, Inc., No. 1:19-cv-01282 (D. Del.).